ClinicalTrials.gov
ClinicalTrials.gov Menu

PREPARE (A5361s) Substudy of REPRIEVE (A5332) (PREPARE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03070223
Recruitment Status : Active, not recruiting
First Posted : March 3, 2017
Last Update Posted : September 19, 2018
Sponsor:
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute on Aging (NIA)
Information provided by (Responsible Party):
AIDS Clinical Trials Group

Brief Summary:
Aging with HIV may be related to an earlier development of frailty (weakness) or disability, including difficulties in tests of strength or walking speed. Few treatments have been shown to prevent or slow these impairments in people with or without HIV. Some studies have suggested that the class of drugs called statins (for example, pitavastatin) might be helpful in slowing frailty or disability. This might happen by decreasing fat within the muscle or by decreasing inflammation markers (substances in the blood that determine how the body reacts to infection or irritation) in the blood. Other studies have shown that statins increase the risk of muscle aches and pains. This substudy is being done to determine the impact of the drug pitavastatin on muscle.

Condition or disease Intervention/treatment
HIV-1 Infection Drug: Pitavastatin Drug: Placebos

Detailed Description:

A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants enrolled in both REPRIEVE (A5332) and its mechanistic sub-study A5333s or in REPRIEVE (A5332) alone and follow them for 48 months after entry to REPRIEVE (A5332). Treatment groups (pitavastatin vs placebo) will be defined according to randomization in REPRIEVE (A5332). No intervention will be provided in this sub-study.

Study visits are scheduled at PREPARE (A5361s) entry and at months 12, 24, 36 and 48 after REPRIEVE (A5332) entry. Each study visit will include evaluation of physical function, frailty and self-reported physical activity and sedentary time. In addition, demographic and clinical data, laboratory specimens and CT scans collected as part of the main study REPRIEVE (A5332) or its mechanistic sub-study A5333s will be used.


Study Type : Observational
Actual Enrollment : 602 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Actual Study Start Date : February 28, 2017
Estimated Primary Completion Date : February 28, 2022
Estimated Study Completion Date : February 28, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Group/Cohort Intervention/treatment
Experimental: Pitavastatin
Participants who receive pitavastatin in the main study REPRIEVE (A5332).
Drug: Pitavastatin
One tablet (4 mg) taken once daily, orally with or without food

Placebo Comparator: Placebo
Participants who receive placebo for pitavastatin in the main study REPRIEVE (A5332).
Drug: Placebos
One tablet taken once daily, orally with or without food




Primary Outcome Measures :
  1. Rate of change in chair rise rate [ Time Frame: Baseline and months 12, 24, 36 and 48 ]
    Participants will be asked to perform 10 chair stands. Chair rise rate will be calculated as time to perform chair stands divided by the number of chair stands performed. . Repeated measures analysis will be used to model chair rise rate over time and estimate rate of change.

  2. Rate of change in Inflammatory Index Score (IIS) [ Time Frame: Baseline and 12 months ]
    The IIS score will be calculated as 1/3 log [interleukin-6 (IL-6)] + 2/3 log [soluble tumor necrosis factor receptor 1 (sTNFR-1)] using samples collected as part of the main study REPRIEVE (A5332).

  3. Rate of change in paraspinal muscle density [ Time Frame: Baseline and 24 months ]
    Paraspinal muscle density will be measured in Hounsfield units (HU) from the CT scans performed as part of A5333s, the mechanistic sub-study of REPRIEVE (A5332).


Secondary Outcome Measures :
  1. Physical function outcome measure: Grip strength [ Time Frame: Baseline and months 12, 24, 36 and 48 ]
    Participant's grip strength in the dominant hand measured by Jamar Hydraulic Hand Dynamometer.

  2. Physical function outcome measure: Gait speed [ Time Frame: Baseline and months 12, 24, 36 and 48 ]
    Participant's gait speed evaluated by time to complete 4-meter walk.

  3. Physical function outcome measure: Balance [ Time Frame: Baseline and months 12, 24, 36 and 48 ]
    Balance evaluated by participant's ability to hold one leg stand for 30 seconds.

  4. Physical function outcome measure: Physical function deficit [ Time Frame: Baseline and months 12, 24, 36 and 48 ]
    Physical function deficit defined as composite Short Physical Performance Battery (SPPB, consisting of repeat chair stand, balance, grip strength and gait speed tests) score <=10.

  5. Physical function outcome measure: Self-reported physical activity [ Time Frame: Baseline and months 12, 24, 36 and 48 ]
    Self-reported physical activity evaluated by the questionnaire "Rapid Eating and Activity Assessment for Patients" (REAP).

  6. Mechanistic outcome measure: Serum concentrations of biomarkers [ Time Frame: Baseline and month 12 ]
    Select biomarkers including each individual biomarker of the IIS (IL-6, sTNFR-1) as well as other biomarkers implicated in the pathogenesis of physical function impairment or those that may mediate the effects of statins on systemic inflammation. The specific list of biomarkers of interest will be finalized closer to the time of analysis, incorporating the developments in the field over the next few years.

  7. Mechanistic outcome measure: Shoulder muscle density [ Time Frame: Baseline and month 24 ]
    Shoulder muscle density measured in Hounsfield units (HU) from the CT scans performed as part of A5333s, the mechanistic sub-study of REPRIEVE (A5332).

  8. Mechanistic outcome measure: Upper back muscle density [ Time Frame: Baseline and month 24 ]
    Upper back muscle density measured in Hounsfield units (HU) from the CT scans performed as part of A5333s, the mechanistic sub-study of REPRIEVE (A5332).

  9. Mechanistic outcome measure: Paraspinal muscle volume [ Time Frame: Baseline and month 24 ]
    Paraspinal muscle volume (area) measured from the CT scans performed as part of A5333s, the mechanistic sub-study of REPRIEVE (A5332).

  10. Mechanistic outcome measure: Trunk muscle volume [ Time Frame: Baseline and month 24 ]
    Trunk muscle volume (area) measured from the CT scans performed as part of A5333s, the mechanistic sub-study of REPRIEVE (A5332).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
It is desired that a substantial proportion of participants are enrolled in A5333s.
Criteria

Inclusion Criteria:

  • Ambulatory participants enrolled in both REPRIEVE (A5332) and its Mechanistic Substudy (A5333s) or ambulatory participants who are newly enrolling into REPRIEVE (A5332) at A5333s ACTG sites.

Exclusion Criteria:

  • Inability to ambulate independently (use of a cane or a walker is permitted) or rise from a chair without assistance.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03070223


  Show 33 Study Locations
Sponsors and Collaborators
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute on Aging (NIA)
Investigators
Study Chair: Todd Brown, MD, PhD Johns Hopkins University
Study Chair: Kristine Erlandson, MD University of Colorado, Denver

Responsible Party: AIDS Clinical Trials Group
ClinicalTrials.gov Identifier: NCT03070223     History of Changes
Other Study ID Numbers: ACTG A5361s
UM1AI068636 ( U.S. NIH Grant/Contract )
First Posted: March 3, 2017    Key Record Dates
Last Update Posted: September 19, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Pitavastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Lipid Regulating Agents